October 20, 2023 7:40am

Which suppresses a value directional; the take-away, don’t dwell on what’s happened but, learn the lesson of investing in those who define and meet short-term expectation

Pre-Open Indications: 2 Positive and 2 Negative Indications

Access insight into sector sentiment and share pricing! The time has come to SUBSCRIBE!  Can you afford not to?

I am right more often than not and investors have always been able to count on … RMi for return on investment (ROI); start thinking return on speculation!

Never leave an investor uninformed!

8:00 a.m. edition

 

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session. My interpretation of the morning’s numbers is written to be informative; it’s built on what could happen or materialize

Instead of harping on NOT buying the right names at the right time or NOT waiting long enough to take profit, I suggest dropping the "shoulda, coulda, wouldas" and thinking about where your portfolio is most vulnerable!

 

The pre-open Dow futures are DOWN -0.20% or (-66 points), the S&P is DOWN -0.20% or (-8 points) as the Nasdaq is DOWN -0.27% or (-40 points)

Stock futures are diving Friday morning,

European equity markets opened at a seven-month low,

Asia-Pacific markets were all lower.

 

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

Thursday, indexes turned higher to slide as the close approached as the Dow closed DOWN -250.91 points or -0.75%, the S&P closed DOWN -36.60 points or -0.85% while the Nasdaq closed DOWN -128.13 points or -0.96%

 

Thursday’s (10/19) RegMed Investors’ (RMi) closing bell: “RegMed Investors (RMi) Closing Bell: buyers, wherefore art thou? I’m occasionally retellings of “Romeo and Juliet” about our sector, the question is; who are the sellers or when should buyers purchase downtrodden equities. “Deny thy pricing and refuse thy orders or if thou wilt not be but sworn” … https://www.regmedinvestors.com/articles/13173

 

RegMed Investors (RMi) Research Note: Beam Therapeutics (BEAM) reduces headcount … https://www.regmedinvestors.com/articles/13172

RegMed Investors (RMi) Research Note: Ultragenyx Pharmaceutical (RARE) has priced its public offering at $30.00 per share of 8,33 M stock … https://www.regmedinvestors.com/articles/13168

RegMed Investors (RMi) Research Note: Q3/23 earnings reporting dates, net losses, cash positions and runway outcomes. LPS (loss-per-share) releases will present challenges to share pricing with outcomes included.” … https://www.regmedinvestors.com/articles/13166

 

 

Ebb and flow:

Q4: October – 6 positive and 8 negative closes

Q3:

·         September – 1 holiday, 8 positive and 12 negative closes

·         August – 9 positive and 14 negative closes

·         July - 1 holiday, 12 positive and 8 negative close

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Positive indications;

Thursday’s closing price, some Wednesday, Tuesday, Monday, Friday, last Monday and the previous Wednesday’s closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Beam Therapeutics (BEAM) closed down -$2.44 after Wednesday’s -$1.47 with a positive +$0.05 or +0.27% pre-open indication.

Verve Therapeutics (VERV) closed down -$1.30 after Wednesday’s -$0.58, Tuesday’s -$0.05 and Monday’s -$0.13 with a positive +$0.17 or +1.71% aftermarket indication.

 

Negative Indications:

Thursday closing price, some Wednesday, Tuesday, Monday, Friday, last Monday and the previous Wednesday’s closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

BioLife Solutions (BLFS) closed down -$0.43 with a neutrL$0.00 or 0% aftermarket indication due to CEO Mike Rice who is retiring.

CRISPR Therapeutics (CRSP) closed down -$0.65 after Wednesday’s -$3.23, Tuesday’s -$1.15 and Monday’s +$0.50 with a negative -$0.21 or -0.53% aftermarket indication.

 

The BOTTOM LINE: Cell and gene therapy sector equities that got “whacked” yesterday (Thursday) on the knuckles, today should be the start of getting a pat on the head!

  •  Indexes ended solidly lower on Thursday, with Treasury yields surging as Fed Chair Powell spoke about monetary policy and investors worried whether interest rates would stay higher for longer.

Ben Graham used to talk about the stock market being a cross between a voting machine and a weighing machine.

  • There is the voting machine of this sector. In the short run, values can be pretty senseless if one side or the other decides to be aggressive in their buying or selling.
  • Investors should be cautious about new buys with the market rally struggling and earnings season picking up steam. Selling some recent buys may be warranted.
  • The Cboe Volatility index jumped to its highest close since March; Thursday was up +1.40 points or +7.28% at 20.62.
  • Small caps got bitten by the bears after trying to rally, with the Russell 2000 falling 1.5%. The index has seen its 50-day line undercut the 200-day moving average, a negative sign. Growth stocks were given the harshest spanking, with the Innovator IBD 50 ETF (FFTY) sliding 2.3%. <IBD>

 

An appropriate quote, “We're in a period of sector rotation, and people are trying to figure out in this new environment - in a full reset of rates across the curve - what are the stocks that are going to continue to do well and what are the stocks that are going to suffer." <Rick Meckler, partner at Cherry Lane Investments, a family investment office in New Vernon, New Jersey>

 

Today’s relevancy

  • Trade any ups, buy into some bottoms, build cash position; buying the lows so they can eventually be the overbought through unbridled speculation and then trade again.
  • Mounting tensions in the Middle East stoked risk aversion. Safe-haven gold hit its highest level in more than two months. The Cboe Volatility index (VIX), Wall Street's fear gauge, jumped.

 

What the sector patterns and markets are telling me:

  • Market breadth has been weak
  • Uncertainty
  • A weak aftermarket
  • A sentiment factor driven by algorithms and electronic trading,
  • Remember, the closer we get to earnings releases <LPS or loss per share sweepstakes> the leaner gains or expressive losses are going to be!
  • The ongoing Israel-Hamas war has raised questions of a potential oil supply crunch and a resulting rise in fuel prices if the geopolitical instability spreads to neighboring oil producers in the region.

 

Weekly Economic Data Calendar … Friday - No notable economic releases.

I hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I am more frequently right than consequentially wrong but, I am mostly EARLY!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.